Bard Associates’s Bioventus BVS Stock Holding History

Bard Associates’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.68K	Hold	708	–	–	﹤0.01%	246
2026 Q1	$6.46K	Hold	708	–	–	﹤0.01%	221
2025 Q4	$5.27K	Buy	+708	New	+$5.09K	﹤0.01%	219

Other funds holding BVS

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

JIC

Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bard Associates's BVS Position: Q2 2026 in Review

Bard Associates held its Bioventus (BVS) position steady in Q2 2026 at 708 shares worth $6.68K. The position accounts for ﹤0.01% of the portfolio, ranked #246.

Bard Associates first reported a position in BVS in Q4 2025 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold BVS as of Q2 2026.

Bard Associates held 708 shares of Bioventus worth $6.68K as of Q2 2026.
Bard Associates left its Bioventus share count unchanged in Q2 2026.
Bioventus made up ﹤0.01% of Bard Associates's portfolio in Q2 2026, its #246 holding.
Bard Associates first reported a position in Bioventus in Q4 2025 and has held it in 3 quarters since.
157 funds tracked by Wall St. Rank held Bioventus as of Q2 2026.

Based on Bard Associates's 13F filing for Q2 2026, filed 12 Aug 2026.